Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

DarioHealth Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

DarioHealth şirketinin toplam hissedar öz sermayesi $68.1M ve toplam borcu $28.6M olup, bu da borç-öz sermaye oranını 42.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $122.1M ve $54.1M dir.

Anahtar bilgiler

42.1%

Borç/özkaynak oranı

US$28.63m

Borç

Faiz karşılama oranı	n/a
Nakit	US$22.94m
Eşitlik	US$68.06m
Toplam yükümlülükler	US$54.08m
Toplam varlıklar	US$122.13m

Son finansal sağlık güncellemeleri

Is DarioHealth (NASDAQ:DRIO) Using Debt Sensibly?

Oct 07

DarioHealth (NASDAQ:DRIO) Is Using Debt Safely

Oct 05

Recent updates

A Piece Of The Puzzle Missing From DarioHealth Corp.'s (NASDAQ:DRIO) 27% Share Price Climb

Oct 03

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues Pushing Shares 30% Lower

Aug 09

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues

May 31

DarioHealth Corp. (NASDAQ:DRIO) Shares Could Be 23% Below Their Intrinsic Value Estimate

Feb 16

Time To Worry? Analysts Just Downgraded Their DarioHealth Corp. (NASDAQ:DRIO) Outlook

Nov 06

Is DarioHealth (NASDAQ:DRIO) Using Debt Sensibly?

Oct 07

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues Pushing Shares 28% Lower

Aug 16

Need To Know: Analysts Just Made A Substantial Cut To Their DarioHealth Corp. (NASDAQ:DRIO) Estimates

Aug 15

DarioHealth Corp. (NASDAQ:DRIO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 13

DarioHealth (NASDAQ:DRIO) Is Using Debt Safely

Oct 05

Need To Know: The Consensus Just Cut Its DarioHealth Corp. (NASDAQ:DRIO) Estimates For 2022

Aug 24

DarioHealth Q2 2022 Earnings Preview

Aug 12

DarioHealth: Paying 1.6x Equity Value For Cash Flows Priced Into The Future

Jul 29

At US$8.95, Is It Time To Put DarioHealth Corp. (NASDAQ:DRIO) On Your Watch List?

Feb 11

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: DRIO 'nin kısa vadeli varlıkları ( $39.3M ) kısa vadeli yükümlülüklerini ( $17.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: DRIO şirketinin kısa vadeli varlıkları ( $39.3M ) uzun vadeli yükümlülüklerini ( $36.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: DRIO 'nin net borç/öz sermaye oranı ( 8.4% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: DRIO şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 42.1% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: DRIO şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: DRIO serbest nakit akışı her yıl % 22 1.6 yıl yetecek nakit akışına sahip olacaktır.

DarioHealth Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

DarioHealth Corp. Receives A Written Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Is DarioHealth (NASDAQ:DRIO) Using Debt Sensibly?

DarioHealth (NASDAQ:DRIO) Is Using Debt Safely

Recent updates

A Piece Of The Puzzle Missing From DarioHealth Corp.'s (NASDAQ:DRIO) 27% Share Price Climb

DarioHealth Corp. Receives A Written Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Price target decreased by 21% to US$3.83

Consensus revenue estimates decrease by 18%, EPS upgraded

Consensus revenue estimates decrease by 21%, EPS upgraded

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues Pushing Shares 30% Lower

DarioHealth Corp. to Report Q2, 2024 Results on Aug 08, 2024

Consensus EPS estimates fall by 11%, revenue upgraded

DarioHealth Corp. Announces Management Changes

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 16%, EPS upgraded

DarioHealth Corp. to Report Q1, 2024 Results on May 15, 2024

DarioHealth Corp. Publishes New Peer-Reviewed Study That Deepens the Body of Evidence That Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes

Consensus EPS estimates upgraded to US$1.71 loss, revenue downgraded

DarioHealth Corp. Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health

Consensus EPS estimates fall by 29%

Full year 2023 earnings released: US$2.24 loss per share (vs US$2.54 loss in FY 2022)

DarioHealth Corp. to Report Fiscal Year 2023 Results on Mar 28, 2024

DarioHealth Corp. Announces Two New Clinical Studies Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes 2024

DarioHealth Corp. announced that it has received $22.422 million in funding

DarioHealth Corp. (NasdaqCM:DRIO) acquired Twill, Inc. for $34.4 million.

DarioHealth Corp. (NasdaqCM:DRIO) acquired Twill, Inc. for $34.4 million.

DarioHealth Corp. (NasdaqCM:DRIO) acquired Twill, Inc. for $34.4 million.

DarioHealth Corp. (NASDAQ:DRIO) Shares Could Be 23% Below Their Intrinsic Value Estimate

Now 20% undervalued after recent price drop

Now 23% undervalued after recent price drop

Consensus revenue estimates fall by 18%

Time To Worry? Analysts Just Downgraded Their DarioHealth Corp. (NASDAQ:DRIO) Outlook

DarioHealth Corp. Provides Revenue Guidance for the Year 2024

DarioHealth Corp. Provides Revenue Guidance for the Year 2024

Third quarter 2023 earnings released: US$0.59 loss per share (vs US$0.70 loss in 3Q 2022)

DarioHealth Corp. to Report Q3, 2023 Results on Nov 02, 2023

DarioHealth Corp., Annual General Meeting, Dec 11, 2023

New minor risk - Share price stability

Is DarioHealth (NASDAQ:DRIO) Using Debt Sensibly?

Market Cool On DarioHealth Corp.'s (NASDAQ:DRIO) Revenues Pushing Shares 28% Lower

Need To Know: Analysts Just Made A Substantial Cut To Their DarioHealth Corp. (NASDAQ:DRIO) Estimates

DarioHealth Corp. (NASDAQ:DRIO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

DarioHealth Corp. to Report Q2, 2023 Results on Aug 10, 2023

DarioHealth Corp. Announces the Presentation of Research at the American Diabetes Association 83(rd) Scientific Sessions

Price target decreased by 13% to US$10.20

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

DarioHealth Corp. announced that it has received funding

DarioHealth Corp. to Report Q1, 2023 Results on May 11, 2023

Consensus EPS estimates upgraded to US$1.75 loss, revenue downgraded

Full year 2022 earnings released: US$2.70 loss per share (vs US$4.75 loss in FY 2021)

DarioHealth Corp. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

DarioHealth Corp. Announces Termination of Dror Bacher, Chief Operating Officer

DarioHealth Corp. Announces Matt Alberico as Senior Vice President of Growth

Independent Director notifies of intention to sell stock

Price target decreased to US$15.02

High number of new and inexperienced directors

DarioHealth Corp. to Report Q3, 2022 Results on Nov 14, 2022

DarioHealth Corp., Annual General Meeting, Dec 07, 2022

DarioHealth (NASDAQ:DRIO) Is Using Debt Safely

DarioHealth Corp. Publishes New Clinical Research Linking the Use of Its Biofeedback Device to Reduced Back Pain

Need To Know: The Consensus Just Cut Its DarioHealth Corp. (NASDAQ:DRIO) Estimates For 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$16.64

DarioHealth Q2 2022 Earnings Preview

DarioHealth Corp. to Report Q2, 2022 Results on Aug 15, 2022

DarioHealth: Paying 1.6x Equity Value For Cash Flows Priced Into The Future

DarioHealth Corp. announced that it has received $25 million in funding from OrbiMed Advisors LLC

DarioHealth Corp. Announces Demise of Richard Stone, Member of the Board of Directors and Appoints Dennis Matheis to Serve as a Member of the Company's Audit Committee as Well as a Member, and Chair, of the Company's Corporate Governance and Nominating Committee

DarioHealth Corp. Presents Three New Studies Demonstrating Improved Health in Users with Multiple Conditions at the American Diabetes Association's 82nd Scientific Sessions

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

DarioHealth Corp. to Report Q1, 2022 Results on May 12, 2022